No announcement yet.

Intranasal inoculate of influenza virus vaccine against lethal virus challenge

  • Filter
  • Time
  • Show
Clear All
new posts

  • Intranasal inoculate of influenza virus vaccine against lethal virus challenge

    Vaccine. 2018 Jun 4. pii: S0264-410X(18)30739-4. doi: 10.1016/j.vaccine.2018.05.075. [Epub ahead of print]
    Intranasal inoculate of influenza virus vaccine against lethal virus challenge.

    Fan X1, Su Q2, Qiu F3, Yi Y4, Shen L5, Jia Z6, Liang P7, Zou Y8, Bi S9.
    Author information


    Vaccine adjuvants are essential for enhancing immune responses during vaccination. However, only a limited number of safe and effective adjuvants, especially mucosal adjuvants, are available for use in vaccines. The development of a practically applicable mucosal adjuvant is therefore urgently needed. Here, we showed that the non-toxic CTA1-DD adjuvant, which combined the full enzymatic activity of the A1 subunit of cholera toxin (CT) with two immunoglobulin-binding domains of Staphylococcus aureus protein A (SpA), promoted mucosal and systemic humoral and cell-mediated immune responses following intranasal administration with H1N1 split vaccine in mice. We demonstrated that CTA1-DD-adjuvant vaccine provided 100% protection against mortality and greatly reduced morbidity in a mouse model. We also showed that addition of CTA1-DD to the vaccine elicited significantly higher hemagglutination inhibition titers and IgG antibodies in sera than alum adjuvant. Furthermore, CTA1-DD significantly promoted the production of mucosal secretory IgA in lung lavages and vaginal lavages. We also showed that CTA1-DD could be used as a mucosal adjuvant to enhance T cell responses. Our results clearly indicated that CTA1-DD contributed to the elicitation of a protective cell-mediated immune response required for efficacious vaccination against influenza virus, which suggested that this adjuvant could be explored further as a clinically safe mucosal vaccine adjuvant for respiratory diseases and other mucosal diseases.


    CTA1-DD; H1N1; Influenza vaccine; Mucosal adjuvant

    PMID: 29880240 DOI: 10.1016/j.vaccine.2018.05.075